CPT1A and ovarian cancer: However, neither CPT1A nor FASN have been reported to correlate with paclitaxel resistant in ovarian cancer, and to the best of our knowledge, there is no research about SCD participating in drug resistance in ovarian cancer, yet it regulates sorafenib resistance via the modulation of ER stress-induced differentiation in hepatocellular carcinomas (HCCs) [64] Our systematic research of the three targets associated with paclitaxel resistance in ovarian cancer is important in understanding the detailed mechanisms of paclitaxel resistance occurrence.